SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021.
The posters will provide preclinical updates on APVO603 and Aptevo's newest pipeline candidate, APVO442.
Title: APVO603: A Dual 4-1BB and OX40 bispecific approach utilizing ADAPTIR technology designed to deliver a conditional T cell/NK response against solid tumors (LB173)
Summary: The data to be presented will highlight the potential benefits of dual targeting of 4-1BB and OX40 by APVO603. In vitro data includes demonstration of APVO603's ability to reduce or reverse the negative effects of T-cell exhaustion and suppressive immune responses by augmenting cytokine production and reducing markers of T-cell exhaustion following repeat stimulation. In preclinical in vivo studies, APVO603 therapy induced a dose-dependent anti-tumor response and significantly increased the survival of mice in a murine bladder cancer model. A non-GLP NHP PK/Tox study was completed and it was found that APVO603 had a favorable safety profile without liver toxicity and a PK profile that supports clinical dosing. CMC activities are in progress and IND-enabling studies are underway to progress the program towards clinical development.
Title: APVO442: A bispecific T cell-engaging candidate utilizing the ADAPTIR-FLEX platform technology with unique properties designed to optimize drug tumor distribution and cytotoxic response against PSMA-expressing solid tumors
Summary: The data to be presented will highlight the unique properties of APVO442, Aptevo's first molecule utilizing our ADAPTIR-FLEX technology, designed with low affinity, monovalent targeting of CD3 and high affinity, bivalent targeting of PSMA to potentially reduce safety signals and improve efficacy for treatment of a solid tumor. In vitro, APVO442 retains strong binding to tumor cell lines with a range of (high to low) surface PSMA expression, and demonstrates reduced binding to CD3+ T cell lines when compared to higher affinity CD3 binding molecules. In vitro efficacy studies show that, despite lower CD3 binding affinity, APVO442 elicits equivalent T-cell activation, proliferation, and cytotoxicity against PSMA+ tumor cells, while limiting cytokine release, when compared to higher affinity CD3 engaging molecules. In vivo, APVO442 demonstrated a dose-dependent ability to limit tumor burden at responses comparable to a high affinity T-cell engager response in a murine xenograft PSMA+ prostate cancer model. APV0442 retains key manufacturability characteristics of the ADAPTIR platform and preclinical data to support the potential for a beneficial safety and efficacy profile. Continued pre-clinical evaluation and CMC efforts are ongoing to progress APVO442 toward clinical development.
Details of the e-Poster Presentations: The abstracts and the accompanying e-posters will be available in the Virtual Poster Hall to registered attendees from 8:30 am EST on Saturday, April 10th, 2021, until the Virtual Poster Hall closes on Monday June 21st, 2021. Chat and live meeting requests will be available for questions and discussion with the presenters. Details can be found on the AACR abstract website and will also be posted on the Aptevo Therapeutics website.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIRTM modular protein platform technology. APVO442 was developed based on the new ADAPTIR-FLEXTM platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating highly differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity of its pre-clinical candidates and potential use as a therapeutic, advancement of its clinical trials and its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and enrollment of future clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19). Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission ("SEC"), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement.
Email: [email protected]
SOURCE: Aptevo Therapeutics Inc.